GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jiangsu Recbio Technology Co Ltd (FRA:G93) » Definitions » Loans Receivable

Jiangsu Recbio Technology Co (FRA:G93) Loans Receivable : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Jiangsu Recbio Technology Co Loans Receivable?

Jiangsu Recbio Technology Co's Loans Receivable for the quarter that ended in Dec. 2024 was €0.00 Mil.


Jiangsu Recbio Technology Co Loans Receivable Historical Data

The historical data trend for Jiangsu Recbio Technology Co's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Recbio Technology Co Loans Receivable Chart

Jiangsu Recbio Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable
Get a 7-Day Free Trial - - - - -

Jiangsu Recbio Technology Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Jiangsu Recbio Technology Co Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Jiangsu Recbio Technology Co Loans Receivable Related Terms

Thank you for viewing the detailed overview of Jiangsu Recbio Technology Co's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangsu Recbio Technology Co Business Description

Traded in Other Exchanges
Address
No. 888 Yaocheng Avenue, Medical High-tech District, Jiangsu Province, Taizhou, CHN
Jiangsu Recbio Technology Co Ltd is a vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. The company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.

Jiangsu Recbio Technology Co Headlines

No Headlines